Boehringer deal enables Bridge to expand pipeline, take in-house programs further

In the latest sign of success for Bridge's strategy to translate first-in-class compounds discovered in Asia, the Korean biotech granted Boehringer exclusive global rights to its lung fibrosis candidate BBT-877.

The partnership is the second out-licensing deal for Bridge Biotherapeutics Inc. (Seongnam, South Korea), which in-licenses late discovery molecules primarily from academic institutions, biotechs or pharmas in South Korea, China and Japan; develops them through Phase IIa proof-of-concept; and then partners the compounds (see "Pellino Play"). ...